Karma Biotechnologies

LNP technology that can deliver both DNA and RNA payloads to solid tumor microenvironments

Based based in United States, Karma Biotechnologies works in human health, founded in 2017.

Profile

Karma is an in vivo cell therapy company that uses a proprietary LNP technology to reprogram key immune cells to infiltrate tumors and break down their defenses from within. Karma’s ionizable LNPs can target and reprogram macrophages within the spleen using DNA., RNA, or both, which can then home to tumor sites and produce therapeutics directly within the tumor microenvironment. Karma’s technology is initially focused on cytokines and other biologicals, such as IL-15, locally within tumors and metastatic sites. Localized IL-15 production can turn cold tumors hot, potentiating immunotherapies while avoiding the dangers of systemic toxicity. Karma will advance through their own internal drug program while also partnering in parallel. The company already has an active paid partnership with a public pharma company and is in post-LOI discussions around another paid partnership early next year.

Its activity falls under human health; the profile below is assembled from public directory data.

The business is associated with United States.

The company is listed at the SOSV portfolio company stage of development.

Recorded headcount: 2-10 employees.

Public records show total funding of about $6M.

Website: karmabiotech.com